Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
86.97
-0.81 (-0.92%)
At close: Jun 2, 2026, 4:00 PM EDT
86.67
-0.30 (-0.34%)
After-hours: Jun 2, 2026, 7:51 PM EDT
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $11.16B in the quarter ending March 31, 2026, with 7.78% growth. This brings the company's revenue in the last twelve months to $45.13B, up 6.59% year-over-year. In the year 2025, Abbott Laboratories had annual revenue of $44.33B with 5.67% growth.
Revenue (ttm)
$45.13B
Revenue Growth
+6.59%
P/S Ratio
3.36
Revenue / Employee
$392,470
Employees
115,000
Market Cap
151.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.33B | 2.38B | 5.67% |
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
| Dec 31, 2019 | 31.90B | 1.33B | 4.34% |
| Dec 31, 2018 | 30.58B | 3.19B | 11.64% |
| Dec 31, 2017 | 27.39B | 6.54B | 31.35% |
| Dec 31, 2016 | 20.85B | 448.00M | 2.20% |
| Jan 2, 2016 | 20.41B | 158.00M | 0.78% |
| Jan 3, 2015 | 20.25B | 590.00M | 3.00% |
| Dec 31, 2013 | 19.66B | 607.00M | 3.19% |
| Dec 31, 2012 | 19.05B | -2.36B | -11.01% |
| Dec 31, 2011 | 21.41B | -13.76B | -39.13% |
| Dec 31, 2010 | 35.17B | 4.40B | 14.31% |
| Dec 31, 2009 | 30.76B | 1.24B | 4.19% |
| Dec 31, 2008 | 29.53B | 3.61B | 13.94% |
| Dec 31, 2007 | 25.91B | 3.44B | 15.30% |
| Dec 31, 2006 | 22.48B | 138.50M | 0.62% |
| Dec 31, 2005 | 22.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medtronic | 35.48B |
| Stryker | 25.27B |
| GE HealthCare Technologies | 20.98B |
| Boston Scientific | 20.61B |
| Koninklijke Philips | 20.34B |
| Zimmer Biomet Holdings | 8.41B |
| Edwards Lifesciences | 6.30B |
| Smith & Nephew | 6.16B |
ABT News
- 6 days ago - Abbott secures CE Mark for Libre Duo, Libre Duo 10 Day - TheFly
- 6 days ago - Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes - PRNewsWire
- 6 days ago - ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening - PRNewsWire
- 7 days ago - Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 - PRNewsWire
- 11 days ago - 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26 - TipRanks
- 18 days ago - Even a High-Priced Market Has Bargains. 10 Undervalued Blue-Chip Stocks. - Barrons
- 19 days ago - 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26 - TipRanks
- 5 weeks ago - Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform - PRNewsWire